

## Appendix: Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

Tammy Northam worked on this submission with support from Michele Zielinski who is the Managing Director at Bladder Cancer Canada. Tammy is the former Executive Director and currently working for Bladder Cancer Canada on an interim project basis.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.


Same as above.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

(total between Sept 1, 2018 – Sept 30, 2020)

Company	Check Appropriate Dollar Range			
	\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000
AstraZeneca				X
BioSyent	X			
Bristol Myers Squibb			X	
Hoffman LaRoche			X	
Johnson and Johnson			X	
Merck				X
Novopharm	X			
Peripharm	X			
Pfizer/EMD Serono - \$0	X			

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.



Name: Michele Zielinski  
 Position: Managing Director  
 Patient Group: Bladder Cancer Canada  
 Date: October 1, 2020